MedTrace Logo

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating

NCT02487550 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2015-07-01

No results posted yet for this study

Summary

The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.

Conditions

  • Renal Neoplasma

Interventions

BIOLOGICAL

DC-CIK

Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.

BIOLOGICAL

IL-2/IFN-α

Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.

Sponsors & Collaborators

  • The First People's Hospital of Changzhou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2028-07-31
Completion
2030-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02487550 on ClinicalTrials.gov